RxDoctor Payments Data

James Haynes, MD

Sleep Medicine · Nashville, TNNPI 1104810274

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,403 of the $1,737 with a category attached, or 80.8%. 6 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 56.5% of the total. Reporting peaked in 2022 at $791 and has fallen 67.3% since, to $259 in 2024.

$1,737in general payments, 2019–2025

Across 78 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$981
  • Harmony Biosciences LLC$612
  • Avadel CNS Pharmaceuticals, LLC$51
  • Philips North America LLC$48
  • Axsome Therapeutics, Inc.$29
  • ZOLL Respicardia, Inc.$17

What the payments were for

  • Travel & lodging$151%
  • Food & beverage$1,40381%
  • Education$31918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,737 in reported general payments places this provider in the 55th percentile of 41 sleep medicine providers in Tennessee.

See all sleep medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$56,648
Medicare patients
438
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate24$522,955
XywavSodium,calcium,mag,pot Oxybate23$465,347
Sodium Oxybate24$388,302
WakixPitolisant Hcl15$126,463
Armodafinil111$8,556
QuviviqDaridorexant Hcl14$6,459
Eszopiclone161$5,800
DayvigoLemborexant11$4,736
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine63$3,555
Doxepin Hcl87$2,758
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine74$2,265
Methylphenidate ErMethylphenidate Hcl19$2,172
Zolpidem Tartrate177$2,097
Trazodone Hcl151$2,048
Pramipexole DihydrochloridePramipexole Di-Hcl152$1,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$612$126,46315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 41 sleep medicine providers in Tennessee.

Other sleep medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →